Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 31 October 2014 | By Alexander Gaffney, RAC,
When you think of the word "book," chances are good it conjures of images of libraries and well-worn tomes. But at the US Food and Drug Administration (FDA), the word is more often associated with several databases used to keep track of critical information about the products regulated by the agency. Its "Orange Book," for example, keeps track of information regarding which products are bioequivalent to other drugs, while its newly launched Purple Book is set to do the same for biosimilar products.
Somewhat lesser known within healthcare product regulation circles is FDA's Red Book. The book, technically a guidance formally known as Toxicological Principles for the Safety Assessment of Food Ingredients, is meant to be a how-to guide for companies to show their food products and additives are safe (i.e. non-toxic) for human consumption. FDA's Center for Food Safety and Applied Nutrition (CFSAN) is required by law to approve all new food or color additives prior to their entry into the market, and evaluates those products based on their probable safety.
The Red Book is, by the standards of other FDA products, updated infrequently. Last updated in 2007, the book has undergone just a handful of updates since its launch in the early 1980s. But now FDA is planning to revisit the document, and potentially broaden its scope to include dietary supplements on a more prominent basis.
In a Federal Register announcement on 30 October 2014, FDA said it will begin soliciting comments regarding its Red Book guidance with the explicit intent of "possibly expanding the scope of the Redbook to include chemical safety assessments for all products over which CFSAN has statutory authority including … dietary supplement ingredients [and] food contaminants."
"We are interested in expanding the scope of the Red Book to emphasize the principles of safety and risk assessment that are shared across different regulatory contexts," FDA explains in the announcement.
Regulators invited comments from the public on four questions:
FDA's Red Book meeting will be held on 9 December 2014. Comments on the proposal are due to FDA by 9 February 2015.
Tags: Red Book, Guidance, Toxicology, Food Safety
Regulatory Focus newsletters
All the biggest regulatory news and happenings.